All In Biotech

Drug Trial Radar · NCT05847179

Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome

A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects With Typical Werner Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.

Conditions

  • Werner Syndrome

Interventions

  • ProgerininDrug

    This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. . There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline to Week 56 (including 4-week follow-up)
  2. Incidence of Treatment-Related Adverse EventsTime frame: Baseline to Week 56 (including 4-week follow-up)
  3. Incidence of Serious Adverse Events (SAEs)Time frame: Baseline to Week 56 (including 4-week follow-up)
  4. Incidence of TEAEs and SAEs leading to discontinuation of study medicationTime frame: Baseline to Week 56 (including 4-week follow-up)
  5. Changes in Blood Chemistry from BaselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  6. Changes in Hematology from BaselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  7. Changes in Urinalysis Results from BaselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  8. Changes in Height (cm) from BaselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  9. Changes in Weight (kg) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  10. Changes in Temperature (°C) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  11. Changes in Pulse Rate (beats per minute) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  12. Changes in Respiratory Rate (breaths per minute) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  13. Changes in Systolic Blood pressure (mmHg) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  14. Changes in Diastolic Blood pressure (mmHg) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  15. Changes in Physical Examination findings from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  16. Change in ECG Ventricular Rate (beats per minute) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  17. Change in ECG PR interval (msec) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  18. Change in ECG QRS interval (msec) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  19. Change in ECG QT interval (msec) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
  20. Change in ECG QTc interval (msec) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.